公开(公告)号：US20240301033A1

公开(公告)日：2024-09-12

申请号：US18436312

申请日：2024-02-08

Applicant: Janssen Biotech, Inc.

Inventor： Rebecca Hawkins ,  Steven Jacobs ,  Manuel Sepulveda

IPC: C07K14/78 ,  A61K49/00 ,  A61K51/08 ,  G01N33/53 ,  G01N33/566 ,  G01N33/569 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K14/78 ,  A61K49/0002 ,  A61K51/088 ,  G01N33/53 ,  G01N33/566 ,  G01N33/569 ,  G01N33/56966 ,  G01N33/574 ,  G01N33/57492 ,  G01N33/68 ,  G01N33/6887 ,  G01N2333/70517 ,  G01N2333/78

Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

公开(公告)号：US20240100129A1

公开(公告)日：2024-03-28

申请号：US18496397

申请日：2023-10-27

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Steven Jacobs ,  Karyn O'Neil ,  Thomas Rutkoski

IPC: A61K38/39 ,  A61K47/54 ,  C07K14/78 ,  C07K16/18 ,  C07K16/40 ,  G01N33/68

CPC classification number: A61K38/39 ,  A61K47/549 ,  C07K14/78 ,  C07K16/18 ,  C07K16/40 ,  G01N33/68 ,  A61K2039/505 ,  C07K2317/94

Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

公开(公告)号：US11702475B2

公开(公告)日：2023-07-18

申请号：US17303425

申请日：2021-05-28

Applicant: Janssen Biotech, Inc.

Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

CPC classification number: C07K16/2863 ,  C07K14/78 ,  G01N33/74 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US11447539B2

公开(公告)日：2022-09-20

申请号：US16801787

申请日：2020-02-26

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Rebecca Hawkins ,  Steven Jacobs ,  Manuel Sepulveda

IPC: C07K14/705 ,  C07K14/71 ,  C07K14/78 ,  A61P35/00 ,  C12N15/85 ,  C07K16/28 ,  A61K38/17 ,  A61K38/39

Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

公开(公告)号：US11345739B2

公开(公告)日：2022-05-31

申请号：US16820844

申请日：2020-03-17

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Rebecca Hawkins ,  Steven Jacobs ,  Manuel Sepulveda

IPC: C07K14/78 ,  G01N33/53 ,  G01N33/574 ,  A61P35/00 ,  C12N15/85 ,  C07K14/705 ,  G01N33/68 ,  C07K14/71 ,  A61K38/39 ,  G01N33/566

Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

公开(公告)号：US11299534B2

公开(公告)日：2022-04-12

申请号：US16821064

申请日：2020-03-17

Applicant: Janssen Biotech, Inc.

Inventor： Rebecca Hawkins ,  Steven Jacobs ,  Manuel Sepulveda

IPC: C07K14/00 ,  C07K14/52 ,  C07K14/78 ,  G01N33/569 ,  G01N33/68 ,  G01N33/566 ,  A61K51/08 ,  G01N33/53 ,  A61K49/00 ,  G01N33/574

Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

公开(公告)号：US20210228688A1

公开(公告)日：2021-07-29

申请号：US17153229

申请日：2021-01-20

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Steven Jacobs ,  Karyn O'Neil ,  Thomas Rutkoski

IPC: A61K38/39 ,  A61K47/54 ,  C07K14/78 ,  C07K16/18 ,  C07K16/40

Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

公开(公告)号：US11072663B2

公开(公告)日：2021-07-27

申请号：US16227597

申请日：2018-12-20

Applicant: Janssen Biotech, Inc.

Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

公开(公告)号：US10925932B2

公开(公告)日：2021-02-23

申请号：US15611296

申请日：2017-06-01

Applicant: Janssen Biotech, Inc.

Inventor： Michael Diem ,  Steven Jacobs ,  Karyn O'Neil ,  Thomas Rutkoski

IPC: C07K14/78 ,  A61K38/39 ,  A61K47/54 ,  C07K16/18 ,  C07K16/40 ,  A61K39/00

Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

公开(公告)号：US20200325210A1

公开(公告)日：2020-10-15

申请号：US16840479

申请日：2020-04-06

Applicant: Janssen Biotech, Inc.

Inventor： Mark Anderson ,  Ricardo Attar ,  Michael Diem ,  Shalom Goldberg ,  Linus Hyun ,  Steven Jacobs ,  Alastair King ,  Donna Klein ,  Sheri Moores ,  Karyn O'Neil ,  Kristen Picha

IPC: C07K14/78 ,  C07K14/71 ,  C12N15/64 ,  C12N15/09 ,  C12N15/63 ,  C07K19/00

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.